Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
GlucoTrack, Inc. develops medical technology for people with diabetes, centered on a long-term, fully implantable continuous blood glucose monitoring system. Company news commonly covers the CBGM platform, FDA Investigational Device Exemption activity, preclinical and clinical-study disclosures, and peer-reviewed publications on sensor stability, accuracy, and implantable device performance.
Updates also include intellectual-property developments for proprietary sensor chemistry, intravascular lead design, and low-power electronics, along with financial results, research and development spending, capital actions, and conference presentations tied to the company’s diabetes device strategy.
Glucotrack (Nasdaq:GCTK) will showcase its fully implantable continuous blood glucose monitoring (CBGM) technology at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans, June 5–8, 2026.
The company highlights direct blood measurements, multi-year implant longevity, no on-body wearables, new peer-reviewed data, and a recent FDA IDE submission.
Glucotrack (Nasdaq:GCTK) reported first quarter 2026 results and progress on its fully implantable continuous blood glucose monitoring (CBGM) program.
Key updates include FDA IDE submission for a U.S. clinical study targeted for 2H 2026, supportive peer-reviewed data, debt reduction, and lower net loss year-over-year.
Glucotrack (Nasdaq: GCTK) submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration on May 7, 2026 to initiate a U.S. clinical study of its fully implantable continuous blood glucose monitoring (CBGM) system. The filing follows preclinical testing and iterative design work and, if approved, would allow clinical evaluation of a long‑term, blood‑based CGM without an on‑body wearable.
Glucotrack says it will proceed with the U.S. study after FDA review and approval and intends to generate clinical data to support future regulatory advancement.
Glucotrack (Nasdaq: GCTK) published a peer-reviewed Journal of Diabetes Research study reporting long-term accuracy and stability of its fully implantable continuous blood glucose monitor in an in-vivo ovine model.
The study implanted 34 devices in 17 sheep for up to 240 days, reporting a weighted average MARD 6.8%, consistent sensing, and no device-related adverse safety events; company also cites first-in-human MARD 7.7% with 99% data capture.
Glucotrack (Nasdaq: GCTK) announced a peer‑reviewed publication in IEEE Sensors Journal (published April 7, 2026) reporting the first year‑long in‑vitro measurement of glucose oxidase deactivation in electrochemical sensors.
The study, done with TTP (UK), examined sensors built to mimic ~two‑year‑old devices and supports the feasibility of long‑life implantable continuous blood glucose monitoring. Glucotrack cited prior first‑in‑human results (MARD 7.7%, 99% data capture) and said the work supports near‑term IDE submission efforts.
Glucotrack (Nasdaq: GCTK) reported 2025 results and development progress on its fully implantable continuous blood glucose monitoring (CBGM) platform. The company received three USPTO patents, completed a $4.0 million private placement, held cash of $7.4 million at year-end, and plans an IDE filing in Q2 2026 to support a U.S. clinical trial in H2 2026.
Full‑year 2025 R&D was $9.8M, G&A $6.3M, and net loss was $19.4M versus $22.6M in 2024. An Australian multicenter feasibility study is underway.
Glucotrack (Nasdaq: GCTK) plans to file an Investigational Device Exemption (IDE) with the FDA in Q2 2026 to support a U.S. clinical trial for its fully implantable continuous blood glucose monitoring (CBGM) system.
Key 2025 milestones: a 10‑patient Brazil first‑in‑human study (Dec 13, 2024–Jan 31, 2025) showing MARD 7.7%, 99% data capture, no device- or procedure-related serious adverse events, an Australia feasibility study, and three US patents issued Oct–Nov 2025 (sensor chemistry, intravascular lead, low‑power electronics). US study initiation is planned for H2 2026, subject to FDA IDE approval.
Glucotrack (Nasdaq: GCTK) will present at LSI USA ’26 in Dana Point, California, March 16–20, 2026. The company presentation is scheduled for Tuesday, March 17 at 8:15 a.m. PT.
CEO Paul V. Goode, PhD, will introduce Glucotrack’s continuous blood glucose monitor (CBGM) technology, share positive first-in-human study results, and outline regulatory and U.S. commercialization plans toward a clinical trial, emphasizing a fully implantable, patient-centric device designed to reduce daily burden for people with diabetes.
Glucotrack (Nasdaq: GCTK) announced that the USPTO issued three patents for its continuous blood glucose monitoring (CBGM) platform, covering sensor chemistry, intravascular lead design, and low-power electronics.
The patents (US 12,453,494; US 12,458,257; US 12,458,258) were issued Oct 28 and Nov 4, 2025, and support the company’s multi-year implantable CBGM commercialization path designed for up to three years of continuous blood glucose measurement.
Glucotrack (Nasdaq: GCTK) entered a securities purchase agreement dated Dec 30, 2025, with a single institutional investor to sell 1,033,591 common shares (or equivalents) plus warrants to buy up to 2,067,182 shares at a combined effective price of $3.87 per share, for aggregate gross proceeds of approximately $4.0 million before fees.
The warrants carry a $3.87 exercise price, expire five years from initial exercise, and are not exercisable until shareholder approval. Closing is expected on or about Dec 31, 2025. Proceeds are planned for working capital and general corporate purposes. Curvature Securities is sole placement agent. The company agreed to file resale registration within 15 days of closing and use efforts to have it effective within 45 days.